Truong Pauline T, Kader Hosam A, Lacy Barbara, Lesperance Mary, MacNeil Mary V, Berthelet Eric, McMurtrie Elissa, Alexander Skaria
Radiation Therapy Program, British Columbia Cancer Agency, Vancouver Island Centre, Victoria, British Columbia, Canada.
Am J Clin Oncol. 2005 Apr;28(2):157-64. doi: 10.1097/01.coc.0000143049.05090.12.
Although the incidence of endometrial cancer increases with age, the effect of patient age on treatment selection and outcomes is unclear. In addition, although aging is associated with increased prevalence of comorbid conditions, the extent to which comorbidities influence endometrial cancer management is not well documented.
This population-based analysis evaluates the effect of age and comorbidity on endometrial cancer treatment and outcome in a cohort of 401 patients referred to the Vancouver Island Centre, British Columbia Cancer Agency from 1989 to 1996. Treatment and 5-year actuarial overall survival (OS) and disease-free survival (DFS) were compared by age at diagnosis (<65, 65-74, and > or =75 years) and comorbidity index (Charlson score 0-1 and > or =2).
Median follow-up time was 7.8 years. In this cohort, 148 (37%), 152 (38%), and 101 (25%) were aged <65, 65-74, and > or =75 years, respectively. Charlson comorbidity scores > or =2 were found in 18% of patients. Distributions of disease stage, tumor characteristics, and surgical therapy were similar across age and comorbidity subgroups. Standard surgery in this cohort comprised hysterectomy without routine lymphadenectomy. In stage Ic disease, the use of postoperative RT declined with advanced age (96%, 97%, and 74% in patients aged <65, 65-74, and > or =75 years, respectively, P = 0.05) and with increased comorbidities (91% and 79% in patients with Charlson score 0-1 and > or =2, respectively, P = 0.07). Among stage Ic patients aged > or =75 years, pelvic/vaginal relapse occurred in 2 of 6 patients treated with hysterectomy alone compared with 0 of 20 patients treated with postoperative radiotherapy (P = 0.006). On multivariable Cox modeling, age at diagnosis, performance status, stage, grade, lymphovascular invasion, surgery, and radiotherapy use, but not Charlson comorbidity score, were significant predictors for overall survival.
Although surgical therapy for endometrial cancer was not influenced by age or comorbidities, reduced use of postoperative radiotherapy in stage Ic disease was observed among women with advanced age and high comorbidity index. The associated pelvic/vaginal relapse rates were higher in elderly patients not treated with radiotherapy. Chronologic age alone should not preclude patients from consideration of optimal local therapy.
尽管子宫内膜癌的发病率随年龄增长而增加,但患者年龄对治疗选择和预后的影响尚不清楚。此外,虽然衰老与合并症患病率增加相关,但合并症对子宫内膜癌治疗的影响程度尚无充分记录。
这项基于人群的分析评估了年龄和合并症对1989年至1996年转诊至不列颠哥伦比亚癌症机构温哥华岛中心的401例患者队列中子宫内膜癌治疗及预后的影响。根据诊断时的年龄(<65岁、65 - 74岁和≥75岁)和合并症指数(Charlson评分0 - 1分和≥2分)比较治疗情况以及5年精算总生存率(OS)和无病生存率(DFS)。
中位随访时间为7.8年。在该队列中,年龄<65岁、65 - 74岁和≥75岁的患者分别有148例(37%)、152例(38%)和101例(25%)。18%的患者Charlson合并症评分为≥2分。疾病分期、肿瘤特征和手术治疗在年龄和合并症亚组中的分布相似。该队列中的标准手术包括不进行常规淋巴结清扫的子宫切除术。在Ic期疾病中,术后放疗的使用随年龄增长而减少(年龄<65岁、65 - 74岁和≥75岁的患者分别为96%、97%和74%,P = 0.05),且随合并症增加而减少(Charlson评分0 - 1分和≥2分的患者分别为91%和79%,P = 0.07)。在≥75岁的Ic期患者中,单纯子宫切除治疗的6例患者中有2例发生盆腔/阴道复发,而术后放疗的20例患者中无复发(P = 0.006)。在多变量Cox模型中,诊断时的年龄、体能状态、分期、分级、淋巴管浸润、手术和放疗使用情况是总生存的显著预测因素,但Charlson合并症评分不是。
尽管子宫内膜癌的手术治疗不受年龄或合并症影响,但在年龄较大和合并症指数较高的Ic期疾病女性中,术后放疗的使用减少。未接受放疗的老年患者相关盆腔/阴道复发率较高。不应仅凭年龄就排除患者接受最佳局部治疗的可能性。